Pipeline

Our companies’ drug candidates range from preclinical to clinical stage, through to commercial sales. Devices, tools, and diagnostics are not included below.

Phase

Preclinical Clinical Commercial Growth
Company Provell Pharmaceuticals
Offering Marketing/Distribution
Product Euthyrox
Stage Commercial
Early development
Late development
Launch phase
Early commercialisation
Late commercialisation
Company Bohus Biotech
Product name Decoria
Offering Hyaluronic acid
Indication Aesthetics
Stage Late commercial
Early development
Late development
Launch phase
Early commercialisation
Late commercialisation
Company Bohus Biotech
Product name Hyamin
Offering Hyaluronic acid
Indication Aesthetics
Stage Late commercial
Early development
Late development
Launch phase
Early commercialisation
Late commercialisation
Company Bohus Biotech
Product name Lubravisc
Offering Hyaluronic acid
Indication Osteoarthritis
Stage Late commercial
Early development
Late development
Launch phase
Early commercialisation
Late commercialisation
Company Bohus Biotech
Product name Microvisc
Offering Hyaluronic acid
Indication Ophthalmology
Stage Late commercial
Early development
Late development
Launch phase
Early commercialisation
Late commercialisation
Company Xspray Pharma
Product candidate Dasynoc (XS004)
Modality Protein kinase inhibitor (amorphous)
Indication CML, ALL
Phase Preparing commercialisation
Preclinical
Bioavailability studies
Approval
Commercialisation
Company Xspray Pharma
Product candidate HyNap-Nilo (XS003)
Modality Protein kinase inhibitor (amorphous)
Indication Oncology
Phase Bioavailability studies
Preclinical
Bioavailability studies
Approval
Commercialisation
Company Egetis Therapeutics
Product candidate Emcitate
Modality Small molecule
Indication MCT8 deficiency
Phase Phase II/III (registrational)
Preclinical
Phase 1
Pivotal studies
Review
Commercialisation
Company Empros Pharma
Product candidate EMP16
Modality Small molecule
Indication Obesity
Phase Phase IIb
Preclinical
Phase 1
Phase 2
Phase 3
Review
Commercialisation
Company Geneos Therapeutics
Product candidate GT-30/31
Modality Personalised DNA vaccine
Indication Hepatocellular carcinoma
Phase Phase Ib/IIa
Preclinical
Phase 1
Phase 2
Phase 3
Review
Commercialisation
Company Egetis Therapeutics
Product candidate Aladote
Modality Small molecule
Indication Liver injury (paraceamol overdose)
Phase Phase IIb/III (pivotal) planned
Preclinical
Phase 1
Phase 2
Phase 3
Review
Commercialisation
Company Xspray Pharma
Product candidate XS008
Modality Protein kinase inhibitor (amorphous)
Indication Oncology
Phase Bioavailabillity studies
Preclinical
Bioavailability studies
Approval
Commercialisation
Company Mendus
Product candidate Vididencel (combined with oral azacitidine)
Modality Allogeneic dendritic cell therapy
Indication AML maintenance
Phase Phase II
Preclinical
Phase 1
Phase 2
Phase 3
Review
Commercialisation
Company Kahr Medical
Product candidate DSP107
Modality Fusion protein
Indication MSS CRC, NSCLC
Phase Phase II
Preclinical
Phase 1
Phase 2
Phase 3
Review
Commercialisation
Company EpiEndo Pharmaceuticals
Product candidate EP395
Modality Small molecule
Indication COPD
Phase Phase IIa
Preclinical
Phase 1
Phase 2
Phase 3
Review
Commercialisation
Company Buzzard Pharmaceuticals
Product candidate Isunakinra
Modality Recombinant protein
Indication Solid tumours
Phase Phase I/IIa
Preclinical
Phase 1
Phase 2
Phase 3
Review
Commercialisation
Company Mendus
Product candidate Vididencel (combined with 5'asa)
Modality Allogeneic dendritic cell therapy
Indication AML maintenance
Phase Phase II
Preclinical
Phase 1
Phase 2
Phase 3
Review
Commercialisation
Company Atrogi
Product candidate ATR-258
Modality Small molecule
Indication T2DM
Phase Phase I
Preclinical
Phase 1
Phase 2
Phase 3
Review
Commercialisation
Company AnaCardio
Product candidate AC01
Modality Small molecule
Indication HFrEF
Phase Phase Ib/IIa
Preclinical
Phase 1
Phase 2
Phase 3
Review
Commercialisation
Company Xintela
Product candidate XSTEM
Modality Allogeneic stem cell therapy
Indication Osteoarthritis
Phase Phase I/IIa
Preclinical
Phase 1
Phase 2
Phase 3
Review
Commercialisation
Company Mendus
Product candidate Vididencel (combined with SoC)
Modality Allogeneic dendritic cell therapy
Indication Ovarian cancer maintenance
Phase Phase I
Preclinical
Phase 1
Phase 2
Phase 3
Review
Commercialisation
Company Kahr Medical
Product candidate DSP107
Modality Fusion protein
Indication AML/MDS
Phase Phase Ib
Preclinical
Phase 1
Phase 2
Phase 3
Review
Commercialisation
Company Sixera Pharma
Product candidate SXR1096
Modality Small molecule
Indication Netherton syndrome
Phase Phase I/II
Preclinical
Phase 1/2
Phase 2/3 (pivotal)
Review
Commercialisation
Company Mendus
Product candidate Ilixadencel (combined with TKI)
Modality Allogeneic dendritic cell therapy
Indication Soft tissue sarcoma
Phase Phase I/II
Preclinical
Phase 1
Phase 2
Phase 3
Review
Commercialisation
Company Lipum
Product candidate SOL-116
Modality Monoclonal antibody
Indication Rheumatoid arthritis
Phase Phase I
Preclinical
Phase 1
Phase 2
Phase 3
Review
Commercialisation
Company Geneos Therapeutics
Product candidate GT-10/20
Modality Personalised DNA vaccine
Indication Glioblastoma multiforme
Phase Phase I
Preclinical
Phase 1
Phase 2
Phase 3
Review
Commercialisation
Company Prokarium
Product candidate NMIBC
Modality Microbial immunotherapy
Indication Bladder cancer
Phase 1/1b
Preclinical
Phase 1
Phase 2
Phase 3
Review
Commercalisation
Company Microbiotica
Product candidate MB097
Modality Live bacterial therapeutic
Indication Immuno-oncology
Phase 1b
Preclinical
Phase 1
Phase 2
Phase 3
Review
Commercalisation
Company Kahr Medical
Product candidate DSP216
Modality Fusion protein
Indication Oncology
Phase Preclinical
Preclinical
Phase 1
Phase 2
Phase 3
Review
Commercalisation
Company Kahr Medical
Product candidate DSP502
Modality Fusion protein
Indication Oncology
Phase Preclinical
Preclinical
Phase 1
Phase 2
Phase 3
Review
Commercalisation
Company Microbiotica
Product candidate MB310
Modality Live bacterial therapeutic
Indication Ulcerative colitis
Phase 1b
Preclinical
Phase 1
Phase 2
Phase 3
Review
Commercalisation
Company Xintela
Product candidate TARG9/10
Modality Antibody drug conjugate
Indication Aggressive cancer
Phase Preclinical
Preclinical
Phase 0 + 1
Phase 2
Phase 3
Review
Commercalisation
Company Toleranzia
Product candidate TOL2
Modality Tolerogen
Indication Myasthenia gravis
Phase Preclinical
Preclinical
Phase 1
Phase 2
Phase 3
Review
Commercalisation
Company Synerkine Pharma
Product candidate SK-01
Modality Fusion protein
Indication Chronic pain, Osteoarthritis
Phase Preclinical
Preclinical
Phase 1
Phase 2
Phase 3
Review
Commercalisation
Company Amarna Therapeutics
Product candidate AM510
Modality Gene therapy
Indication Type 1 Diabetes
Phase Preclinical
Preclinical
Phase 1
Phase 2
Phase 3
Review
Commercalisation
Company Synerkine Pharma
Product candidate SK-02
Modality Fusion protein
Indication CIPN
Phase Preclinical
Preclinical
Phase 1
Phase 2
Phase 3
Review
Commercalisation
Company Prokarium
Product candidate IO Prime
Modality Microbial immunotherapy
Indication Immuno-oncology
Phase Preclinical
Preclinical
Phase 1
Phase 2
Phase 3
Review
Commercalisation
Company Toleranzia
Product candidate TOL3
Modality Tolerogen
Indication ANCA vasculitis
Phase Preclinical
Preclinical
Phase 1
Phase 2
Phase 3
Review
Commercalisation
Company Amarna Therapeutics
Product candidate AMA003
Modality Gene therapy
Indication Multiple sclerosis
Phase Preclinical
Preclinical
Phase 1
Phase 2
Phase 3
Review
Commercalisation
Company Amarna Therapeutics
Product candidate AMA004
Modality Gene therapy
Indication Dry age related macular degeneration
Phase Preclinical
Preclinical
Phase 1
Phase 2
Phase 3
Review
Commercalisation
Company Strike Pharma
Product candidate STRIKE2001-KRAS
Modality ADAC (adapable drug affinity conjugate)
Indication KRAS tumours
Phase Preclinical
Preclinical
Phase 1
Phase 2
Phase 3
Review
Commercalisation
Company Alder Therapeutics
Product candidate AlderEdge platform
Modality Cell therapy
Indication Retinal & cardiac cells
Phase Preclinical
Preclinical
Phase 1
Phase 2
Phase 3
Review
Commercalisation
Company Prokarium
Product candidate RNA delivery platform (Ginkgo Bioworks collab.)
Modality Microbial immunotherapy
Indication Oncology
Phase Preclinical
Preclinical
Phase 1
Phase 2
Phase 3
Review
Commercalisation

Sorry, no results were found.